A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria

• Published in: African journal of medicine and medical sciences Vol. 45; no. 2; p. 179
• Main Authors: Popoola, T D, Awodele, O, Oshikoya, K A
• Format: Journal Article
• Language: English
• Published: Nigeria 01.06.2016
• Subjects: Abdominal Pain - chemically induced; Abdominal Pain - epidemiology; Adolescent; Adult; Anti-HIV Agents - adverse effects; Antiretroviral Therapy, Highly Active - adverse effects; Benzoxazines - adverse effects; Dideoxynucleosides - adverse effects; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections - drug therapy; Humans; Incidence; Lamivudine - adverse effects; Male; Middle Aged; Nausea - chemically induced; Nausea - epidemiology; Nevirapine - adverse effects; Nigeria - epidemiology; Prospective Studies; Sleep Initiation and Maintenance Disorders - chemically induced; Sleep Initiation and Maintenance Disorders - epidemiology; Tenofovir - adverse effects; Young Adult; Zidovudine - adverse effects
• ISSN: 0309-3913

Highly active antiretroviral therapy (HAART); the-current standard of antiretroviral therapy for Human Immunodeficiency Virus (HIV) infected persons, has been documented to drastically, reduce the number of cases of Acquired Immune Deficiency Sypdrome (AIDS). However, adverse. events are a challenge to the use of HAART. This study intends to determine the nature and incidence of suspected advcrse events to prescribed anti retroviral drugs in treatment centers in Ekiti State. One hundred and twenty participants were enrolled and followed up over a period of six months. At each clinic visit, there was an administration of a detailed interviewer questionnaire that was completed by the attending pharmacist together with the participant. The form is designed to obtain information on the demographics of the patients, WHO clinical stage of their HIV infection, HAART regimen for the patients, and suspected adverse events associated with the antiretroviral drugs used by the patients. Tenofovir/Lamivudine/Eifavirenz (72.5%), Zidovudinc/Lamiv.udin/Nevirapine (16.7%), Zidovudine/Lamivudiine/ElafIvirenz (6.7%), Tenofovir/ Lamivudine/Nevirapine (3.3%), and Abacavir/ Lamivudine/Nevirapine (0.8%) were the HAART regimens prescribed to the patients. About half (57%) of the participants reported clinical adverse events; 92% of which were reported within two weeks of HAART initiation. Most of the reported adveise events were nausea (14.5%), abdominal discomfort (8.2%), and insomnia (7.5%). A few (6%) of those who reported adverse events required regimen switch or drug substitution. Antiretroviral drugs exposure often presents with adverse events, an observation similar to other studies. Most of the clinical adverse events were not severe or life threatening.